Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for (131)I Administration

CONTEXT: Recombinant human thyrotropin (rhTSH) is currently not Food and Drug Administration approved for the treatment of high-risk patients with differentiated thyroid cancer (DTC). OBJECTIVE: The goal of our study was to compare the outcomes in higher-risk patients with metastatic DTC prepared fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomes-Lima, Cristiane J, Chittimoju, Sanjita, Wehbeh, Leen, Dia, Sunita, Pagadala, Prathyusha, Al-Jundi, Mohammad, Jhawar, Sakshi, Tefera, Eshetu, Mete, Mihriye, Klubo-Gwiezdzinska, Joanna, Van Nostrand, Douglas, Jonklaas, Jacqueline, Wartofsky, Leonard, Burman, Kenneth D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962448/
https://www.ncbi.nlm.nih.gov/pubmed/35356009
http://dx.doi.org/10.1210/jendso/bvac032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962448/
https://www.ncbi.nlm.nih.gov/pubmed/35356009
http://dx.doi.org/10.1210/jendso/bvac032

Ejemplares similares